David Wu

2.5k total citations · 2 hit papers
21 papers, 1.6k citations indexed

About

David Wu is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, David Wu has authored 21 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Genetics and 4 papers in Hematology. Recurrent topics in David Wu's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers), Analytical Chemistry and Chromatography (2 papers) and Epigenetics and DNA Methylation (2 papers). David Wu is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers), Analytical Chemistry and Chromatography (2 papers) and Epigenetics and DNA Methylation (2 papers). David Wu collaborates with scholars based in United States, United Kingdom and Switzerland. David Wu's co-authors include Lewis C. Cantley, John M. Asara, Kenneth E. Huffman, Ralph J. DeBerardinis, Edouard Mullarky, Ignacio I. Wistuba, Yang Xie, Hao Tang, Zeping Hu and Pei-Hsuan Chen and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Genetics.

In The Last Decade

David Wu

21 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

NRF2 regulates serine biosynthesis in non–small cell lung cancer

2015 560 citations Gina M. DeNicola, Pei-Hsuan Chen et al. Nature Genetics profile →
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors

2018 481 citations Benjamin D. Hopkins, Chantal Pauli et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Wu United States	11	1.1k	510	239	193	169	21	1.6k
Zuoquan Xie China	25	977 0.9×	473 0.9×	147 0.6×	291 1.5×	214 1.3×	68	1.7k
Ying Sun China	24	1.1k 1.0×	392 0.8×	101 0.4×	379 2.0×	207 1.2×	93	2.1k
Rishi Raj Chhipa United States	17	837 0.8×	347 0.7×	82 0.3×	239 1.2×	123 0.7×	20	1.3k
Nikos Koundouros United Kingdom	8	1.1k 1.0×	880 1.7×	99 0.4×	206 1.1×	196 1.2×	11	1.7k
Sung‐Jig Lim South Korea	24	766 0.7×	310 0.6×	89 0.4×	387 2.0×	199 1.2×	69	1.7k
Wai‐Nang Paul Lee United States	19	831 0.8×	511 1.0×	142 0.6×	129 0.7×	64 0.4×	28	1.4k
Changzheng Li China	22	719 0.7×	277 0.5×	76 0.3×	240 1.2×	205 1.2×	78	1.4k
Marco Sciacovelli United Kingdom	22	1.6k 1.5×	803 1.6×	173 0.7×	241 1.2×	188 1.1×	26	2.1k
Julian C. Desmond United States	18	1.0k 1.0×	138 0.3×	75 0.3×	260 1.3×	87 0.5×	25	1.7k
Μolin Wang China	24	647 0.6×	597 1.2×	115 0.5×	745 3.9×	256 1.5×	53	1.8k

Countries citing papers authored by David Wu

Since Specialization

Citations

This map shows the geographic impact of David Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Wu more than expected).

Fields of papers citing papers by David Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Wu. The network helps show where David Wu may publish in the future.

Co-authorship network of co-authors of David Wu

This figure shows the co-authorship network connecting the top 25 collaborators of David Wu. A scholar is included among the top collaborators of David Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Wu. David Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, David & Sebastian Jaimungal. (2023). Robust Risk-Aware Option Hedging. Applied Mathematical Finance. 30(3). 153–174. 3 indexed citations

Stein, Benjamin D., Eric E. Gardner, Jae Won Chang, et al.. (2023). LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma. Cancer Discovery. 13(4). 1002–1025. 20 indexed citations

Wu, David & Sebastian Jaimungal. (2023). Robust Risk-Aware Option Hedging. SSRN Electronic Journal. 2 indexed citations

Patel, Jay, Vikram Attaluri, Joan J. Ryoo, et al.. (2023). Investigating Mortality Disparities Among Insured Patients With Colon Cancer Treated in an Integrated Health care System and Other Private Settings. The American Surgeon. 89(12). 5940–5948. 1 indexed citations

Goncalves, Marcus D., Seo‐Kyoung Hwang, Chantal Pauli, et al.. (2018). Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proceedings of the National Academy of Sciences. 115(4). E743–E752. 85 indexed citations

Hopkins, Benjamin D., Chantal Pauli, Xing Du, et al.. (2018). Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 560(7719). 499–503. 481 indexed citations breakdown →

Neugut, Alfred I. & David Wu. (2018). Cancer Epidemiology and Prevention. 39 indexed citations

Sun, Aining, et al.. (2017). [Clinical significance of JAK2、CALR and MPL gene mutations in 1 648 Philadelphia chromosome negative myeloproliferative neoplasms patients from a single center].. PubMed Central. 38(4). 295–300. 3 indexed citations

Bannow, Bethany Samuelson, Rachel B. Salit, Barry E. Storer, et al.. (2017). Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. Biology of Blood and Marrow Transplantation. 24(2). 386–392. 35 indexed citations

10.

Neugut, Alfred I. & David Wu. (2017). Cancer Epidemiology and Prevention. 9 indexed citations

11.

Wu, David. (2016). Sema4C Expression Characterization and Downstream Signaling in HEK Cells and B Cell Lines. Journal of Allergy and Clinical Immunology. 137(2). AB118–AB118. 1 indexed citations

12.

Qiu, Huiying, et al.. (2016). [EVI1 expression, clinical and cytogenetical characteristics in 447 patients with acute myeloid leukemia].. PubMed. 37(11). 936–941. 1 indexed citations

13.

DeNicola, Gina M., Pei-Hsuan Chen, Edouard Mullarky, et al.. (2015). NRF2 regulates serine biosynthesis in non–small cell lung cancer. Nature Genetics. 47(12). 1475–1481. 560 indexed citations breakdown →

14.

Malhotra, Sheetal, et al.. (2015). National data on sorafenib therapy adherence for veterans with hepatocellular carcinoma.. Journal of Clinical Oncology. 33(15_suppl). 9593–9593. 1 indexed citations

15.

Korth‐Bradley, Joan, et al.. (2014). Comparative Bioavailability Study of Single-Dose Film-Coated and Sugar-Coated Ethionamide Tablets in Healthy Volunteers. Clinical Therapeutics. 36(6). 982–987. 7 indexed citations

16.

Shen, Jing, Shuang Wang, Yujing Zhang, et al.. (2012). Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips. Epigenetics. 8(1). 34–43. 127 indexed citations

17.

Saxe, Gordon A., et al.. (2008). Disclosure to Physicians of CAM Use by Breast Cancer Patients: Findings From the Women's Healthy Eating and Living Study. Integrative Cancer Therapies. 7(3). 122–129. 78 indexed citations

18.

Wu, David, et al.. (2006). Autoimmune Hemolytic Anemia in HIV: A Case Series and Review of the Literature.. Blood. 108(11). 3858–3858. 2 indexed citations

19.

Ornaf, Raphael M., et al.. (1999). Peak fronting in reversed-phase high-performance liquid chromatography: a study of the chromatographic behavior of oxycodone hydrochloride. Journal of Pharmaceutical and Biomedical Analysis. 19(5). 669–678. 20 indexed citations

20.

Tiller, Philip R., Jae C. Schwartz, Ian Jardine, et al.. (1997). Drug quantitation on a benchtop liquid chromatography-tandem mass spectrometry system. Journal of Chromatography A. 771(1-2). 119–125. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact